DailyIQ
Last updatedUpdating…

DXCM·DexCom, Inc.

$85.06
+0.00 (+0.00%)
High
$86.18
Open
$85.89
Market Cap
32.36B
52W High
$92.98
Low
$84.77
P. Close
$85.06
P/E
32.37
52W Low
$54.11
Fwd P/E
27.23
DailyIQ Est.
$100.20
Inst. Ownership
51.3%
Short Interest
3.69%
Days to Cover
3.2
Technical Score (1D)
76
BULLISH
News Sentiment
66
BULLISH
On Oct 13, DexCom (DXCM) projected robust growth driven by its continuous glucose monitoring (CGM) market expansion, citing a 22.6% five‑year growth rate and a strong first‑quarter 2026 performance. The same day, Mizuho Bank raised its price target for DexCom to $100 from $95, noting the company’s improved margin outlook and expanding product pipeline as key reasons for the upgrade. Analysts also highlighted that DexCom’s manufacturing efficiencies and operating leverage were improving profitability, while risks such as factory ramp‑up costs, foreign‑exchange volatility, input‑price pressures, and competitive pressure were acknowledged. A third report on Oct 13 described DexCom as offering affordable growth, with a robust earnings‑per‑share outlook and high profitability metrics that positioned the stock as a quality growth pick relative to peers. Together, these reports underscored DexCom’s strong earnings performance and the market’s positive view of its continued expansion in the CGM space.
LOW TARGET
$79 -6.7%
2 analysts
MEAN TARGET
$96 +13.6%
13 analysts
HIGH TARGET
$115 +35.8%
23 analysts
PRICE RANGE
$79.00 - $115.00
SB / B / H / S / SS
15/16/5/1/1
DAILYIQ EST.
$100.20 (+18.3%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NMS
Country
United States
Website
Symbol
DXCM
Description
DexCom, Inc. is a medical technology firm specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's core offering revolves around its integrated CGM devices, such as the Dexcom G6 and G7, which provide real-time glucose data to patients, caregivers, and healthcare professionals. DexCom also offers supplementary products like Dexcom Share, a remote monitoring system, and the Dexcom Real-Time API, which allows for data integration with third-party digital health applications. Furthermore, DexCom is expanding its product line with offerings like Dexcom ONE and Stelo, designed to broaden access to glucose monitoring. Through direct marketing efforts, DexCom focuses on reaching endocrinologists, physicians, and diabetes educators to promote its innovative solutions.
Bought (1Y)
0 shares
$0
Sold (1Y)
171,201 shares
$13.4M
Stern SadieEVP Chief People & Culture Off
Sell2,565 shares2026-09-28
Brown Michael JonEVP Chief Legal Compliance Off
Sell1,700 shares2026-09-15
AUGUSTINOS NICHOLAS-
Sell6,539 shares2026-09-15
AUGUSTINOS NICHOLAS-
Sell1,550 shares2026-09-14
Sylvain Jereme MEVP, Chief Financal Officer
Sell3,638 shares2026-09-10
80/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
60.1%
Net Margin
17.9%
Revenue CAGR
37.2%
Current Ratio
1.88x
Debt / Equity
0.00x
Return on Equity
30.5%
Earnings Summary

EPS

EstBeatMiss
$0.40$0.49$0.57$0.66$0.74Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.67 - -
Q2'26$0.61$0.70+15.1%
Q1'26$0.47$0.56+19.0%
Q4'25$0.48$0.68+42.8%
Q3'25$0.57$0.61+7.5%
Q2'25$0.44$0.48+8.3%

Revenue

EstBeatMiss
$1.1B$1.2B$1.3B$1.3B$1.4BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.4B - -
Q2'26$1.3B$1.3B+1.4%
Q1'26$1.2B$1.2B+1.5%
Q4'25$1.2B$1.3B+6.5%
Q3'25 - $1.2B -
Q2'25 - $1.2B -

Market Data

DXCM Stock Snapshot

BULLISH76/100
$85.06+$0.00 (0.0%)
Market cap
32.36B
P/E ratio
32.4
Day range
$84.77 – $86.18
News sentiment
66/100 · Bullish
Analyst target
$96.23 (+13.1%)
Consensus
Buy · 38 analysts
52-week range+57.2% off low · -8.5% from high
$54.11$92.98
Price $85.06 DailyIQ Est. $100.20

Momentum is working in DXCM's favour - it ranks in the upper part of DailyIQ's momentum universe. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What DXCM's own history says about today's numbers

Realized volatility (21d)
25.0% 9th pct
Below its peak
-47.8%
vs 200-day average
+15.6%
Up days (1y)
53%

DexCom, Inc. is currently running 25.0% annualised volatility over the last 21 sessions. Measured against DXCM's own 13 years of daily returns rather than a market-wide average, that is the 9th percentile — unusually subdued by its own history, against a typical reading of 37.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

DXCM is trading -47.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -38.9%, and the deepest was -54.4% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +15.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 65th percentile — a somewhat wider gap than its own norm. Over the past year DXCM closed higher on 53% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, DXCM finished the month higher 5 of 13 times, with a median return of -2.6% and an average of +1.3%. Its strongest month historically has been November at +10.1% on average, its weakest September at -7.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: DXCM has opened more than 2% away from the prior close in 134 of 3,266 sessions (4.1% of the time), with the largest gaps running +8.1% and -15.3%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, DXCM moved an average of 5.6% in the session after earnings, closing higher 3 of those 3 times, with a median move of +6.0% and a largest of +8.3%.

All figures computed from 3,267 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against DXCM's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of DXCM's sector?

DexCom, Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, DXCM ranks 3rd of 15 tracked industries, improving.

Sector rank
#3 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#3 of 15

Options Market

What is the options market pricing for DXCM?

CallsPuts

For DexCom, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.98), with at-the-money implied volatility around 66.6%. The options market is pricing roughly a ±4.3% move by that expiry — a range of about $81.40–$88.72.

Put/call ratio (2026-10-16)
0.98
ATM implied volatility
66.6%
Total open interest
4,284
Expected move by 2026-10-16
±4.3% ($81.40–$88.72)

Analyst Rating Changes

Are analysts turning bullish or bearish on DXCM?

BTIG most recently reiterated its rating on DexCom, Inc. to Buy on Oct 12, 2026 with a price target of $96 (from $90). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
BTIG — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026BTIGMaintainedBuy$90 → $96
Oct 7, 2026BarclaysInitiatedOverweight$115
Oct 1, 2026RBC CapitalMaintainedOutperform$90 → $105
Sep 18, 2026Truist SecuritiesMaintainedBuy$93 → $102
Sep 18, 2026TD CowenReiteratedBuy$95
Aug 4, 2026Argus ResearchMaintainedBuy$86 → $96
Aug 3, 2026Canaccord GenuityMaintainedBuy$82 → $90
Jul 31, 2026CitigroupMaintainedBuy$84 → $88
Jul 31, 2026RBC CapitalMaintainedOutperform$85 → $90
Jul 31, 2026MizuhoMaintainedOutperform$90 → $95
Jul 31, 2026JP MorganMaintainedNeutral$65 → $82
Jul 31, 2026Piper SandlerReiteratedOverweight$88 → $95

Peers & ETF holders

DXCM peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

66/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
DexCom, Inc. (DXCM) projected robust growth driven by its continuous glucose monitoring (CGM) market expansion and a 22.6% five‑year growth rate. The company highlighted a strong first‑quarter 2026 performance and an expanding international presence, while noting manufacturing efficiencies and operating leverage as key profitability drivers. Risks cited included factory ramp‑up costs, foreign‑exchange volatility, input‑price pressures, and stiff competition. Despite these headwinds, DexCom’s earnings consistently beat consensus estimates, supporting a positive outlook for the business.
What did this article say?
Mizuho Bank lifted its price target for DexCom (DXCM) to $100 from $95, reflecting a more optimistic view of the company’s prospects. The upgrade follows DexCom’s strong earnings and continued growth in continuous glucose monitoring solutions. Analysts cited improved margin outlook and expanding product pipeline as key drivers for the higher target.
What did this article say?
DexCom (DXCM) was described as offering affordable growth, supported by a robust earnings per share outlook and high profitability. The analysis noted that the company’s valuation remains reasonable relative to its peers, positioning it as a quality growth pick. The commentary emphasized that DexCom’s financial metrics suggest continued upside potential while maintaining a prudent price target.
What did this article say?
DexCom is set to report its third‑quarter earnings, with analysts projecting a high‑single‑digit year‑over‑year increase in earnings per share. The forecast reflects confidence in the company’s product pipeline and market demand. The anticipated growth is expected to support investor expectations and potentially lift the stock price. This outlook underscores DexCom’s continued momentum in the diabetes management sector.
What did this article say?
Citi reaffirmed Dexcom (DXCM) as a leading opportunity in the medical technology sector, citing the company's strong position in continuous glucose monitoring (CGM). The bank highlighted CGM sales of $2 billion in the first quarter, up 7.5%, and projected a return to double‑digit growth in the second quarter. Citi’s endorsement reflects confidence in Dexcom’s near‑term catalysts and the potential for a re‑accelerated growth trajectory, positioning the stock favorably within the broader medtech landscape.
What did this article say?
Evercore ISI increased its price target for DexCom (DXCM) from $90 to $110, reflecting a more optimistic view of the company’s prospects. The rating remains a buy, with the average target now at $96.92 according to FactSet data. The upgrade signals confidence in DexCom’s product pipeline and market positioning, potentially influencing investor expectations.
What did this article say?
Dexcom, Inc. scheduled the release of its third‑quarter 2026 financial results for October 29, 2026, after market close. Management will host a conference call at 4:30 p.m. Eastern to discuss the performance. The call will be webcast and the link will appear on the company’s investor relations site. No earnings guidance or performance updates were provided in the announcement.
What did this article say?
Barclays analyst Christopher Pasquale announced a new coverage of DexCom (NASDAQ:DXCM) with an Overweight rating. The bank set a price target of $115, signaling a bullish outlook for the company. This endorsement reflects confidence in DexCom’s growth prospects and product pipeline, potentially influencing investor sentiment.
What did this article say?
Dexcom, Inc. announced the launch of the fifth season of its Dexcom U NIL program, expanding to 27 college athletes with Type 1 diabetes across 13 sports. The program, now the largest in its history, aims to increase participation and reduce stigma among young athletes. Dexcom will host community events called Dexcom U Days to foster mentorship and engagement. The expansion signals continued growth in the company’s consumer‑focused initiatives and strengthens its brand presence in the sports community.

Technical Analysis

Real-time indicators across multiple timeframes

76
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $12.82B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell49,074,37812.92%$3.26B2026-01-29
BlackRock, Inc.▼ Sell38,244,13710.07%$2.58B2026-08-07
Invesco Ltd.▲ Buy15,288,1334.03%$1.03B2026-08-14
Baillie Gifford & Co▼ Sell14,801,5903.90%$996.89M2026-08-06
Geode Capital Management, LLC▲ Buy12,426,5153.27%$834.17M2026-08-12
AllianceBernstein L.P.▼ Sell11,693,4093.08%$734.35M2026-08-14
Wellington Management Group LLP▼ Sell8,527,4712.25%$574.33M2026-08-14
Norges Bank▼ Sell6,868,0901.81%$462.57M2026-08-12
Morgan Stanley▲ Buy5,156,2821.36%$347.28M2026-08-13
Goldman Sachs Group Inc▲ Buy3,758,6160.99%$253.14M2026-08-14
JPMorgan Chase & Co▼ Sell3,325,0950.88%$232.69M2026-08-12
Northern Trust Corp▼ Sell3,295,1440.87%$221.93M2026-08-13
AQR Capital Management LLC▲ Buy3,237,7200.85%$218.06M2026-08-14
Bank of America Corp▲ Buy3,163,6040.83%$213.07M2026-08-14
Janus Henderson Group plc▲ Buy2,644,5390.70%$166.08M2026-05-18
FMR LLC (Fidelity)▲ Buy1,893,2460.50%$127.51M2026-08-13
Renaissance Technologies LLC▲ Buy1,630,7960.43%$109.83M2026-08-13
Citadel Advisors LLC▼ Sell1,211,7670.32%$81.61M2026-09-02
Susquehanna International Group, LLP▲ Buy1,043,8640.27%$70.30M2026-08-14
Wells Fargo & Company▲ Buy1,011,8690.27%$68.15M2026-08-14
Adage Capital Partners GP, L.L.C.▼ Sell999,9000.26%$67.34M2026-08-14
Citigroup Inc▲ Buy956,3980.25%$64.41M2026-08-03
Neuberger Berman Group LLC▼ Sell736,0240.19%$49.57M2026-08-13
Marshall Wace, LLP▲ Buy532,8040.14%$35.88M2026-08-13
Bridgewater Associates, LP▲ Buy400,9290.11%$27.00M2026-08-14
Q2 2026 flow:11.36M sh bought ($765.15M)9.31M sh sold ($628.18M)net +2.06M sh (+$136.97M)
Congressional Trading Activity
11 disclosed trades · ~$929.5K est. traded value · 4 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
Tina SmithSenateMN▼ Sell$100K - $250K2026-05-072026-05-10
Tina SmithSenateMN▼ Sell$100K - $250K2026-04-292026-05-10
John BoozmanSenateAR▲ Buy$1K - $15K2026-01-262026-02-15
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-05-082025-06-22
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Kevin HernHouseOK01▼ Sell$50K - $100K2024-12-312025-01-15
Tina SmithSenateMN▼ Sell$250K - $500K2020-03-172020-04-16